Donald Hayden

Donald Hayden

Chairman of the Board

Mr. Hayden brings to Vitae the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At BMS, Mr. Hayden served as president of Worldwide Medicines; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group; president of Oncology and Immunology; and senior vice president for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Vitae Pharmaceuticals, Transave Inhalation Biotherapeutics, and Gloucester Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics. He also serves as a senior advisor to Prospect Venture Partners, a leading venture capital firm. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.